Release of CSCO diagnosis and treatment guidelines for malignant lymphoma 2021

In July 2021, the English version of Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 has been published online.

Lymphoma has gradually become one of the high-incidence malignant tumors that threaten the health of the Chinese people. It is estimated that there are 75,400 new cases of lymphoma every year, with an incidence rate of 4.75/100,000. However, the medical resources are not balanced in each area, due to the unbalanced development of the economy, considering factors such as the aging of the population, the burden of lymphoma is increasing in China.

Since 2018, CSCO UCLI has started the development of the CSCO diagnosis and treatment guidelines for malignant lymphoma, which devoted major efforts to push forward a rapid development of standard diagnosis and treatment of lymphoma in China. The guidelines are developed by selected experts specialized in clinical practice, pathology, radiotherapy, and imaging department, and every year, the guidelines are reviewed and updated in accordance with the development of each area, availability of drugs and therapies and social value of the cancer treatment.

The English version of the guidelines retains the overall framework of the Chinese version, including five major parts: General guidelines, Diagnosis, Staging, Treatment, and Prognosis. In the section on treatment, details of treatment for ten types of lymphoma are introduced, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia/small B-cell lymphoma, extranodal NK/T cell lymphoma, peripheral T cell lymphoma, Hodgkin lymphoma, primary central nervous system lymphoma.

Reference:

  1. Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. JHematol Oncol. 2019; 12: 115.
  2. Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12: 22.
  3. http://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2021.03.01?viewType=HTML
Share this article

More Insights